JWH-161
From Self-sufficiency
| 240px | |
| Systematic (IUPAC) name | |
|---|---|
|
(4aR,13bR)-2,5,5-trimethyl-8-pentyl-3,4,4a,5,8,13b-hexahydroisochromeno[3,4-b]carbazol-13-ol | |
| Identifiers | |
| PubChem | CID 10431286 |
| Chemical data | |
| Formula | C27H33NO2 |
| Molar mass | 403.555 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the CB1 receptor. While retaining structural elements from both families, JWH-161 has a CB1 Ki of 19.0nM, although it was found to be slightly weaker than THC in animal tests.[1]
| 40px | This article about a cannabinoid is a stub. You can help ssf by expanding it. |
References
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cannabinoid stubs
- Cannabinoids
- Benzochromenes
- Phenol ethers
- 2Fix
